Mon, Dec 29, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Castle Alternative Invest completes second line share buyback program

Wednesday, October 20, 2010
Opalesque Industry Update - Castle Alternative Invest AG, the global fund of hedge funds investment company listed on the SIX Swiss Exchange and on the London Stock Exchange announced that it has completed the second line share buyback programme initiated on 21 June 2010. Accordingly, the second line on the SIX Swiss Exchange will be closed after market hours on Friday 22 October 2010.

Pursuant to this programme, CAI has repurchased 2,225,464 shares with a total consideration of CHF31.9million representing 5.78% of the shares currently in issue. The average purchase price per share was CHF14.34. This represents 11.29% of the shares that will be in issue after the capital reorganisation noted below. It is intended that a resolution be proposed to the 2011 Annual General Meeting to reduce the capital of the Company by the amount of shares acquired through the second line share buyback programme. After such cancellation, the Company would have 36,275,536 shares in issue, currently corresponding to a market capitalization of approximately CHF468.0 million.

However this capital reduction will be in addition to the capital reorganisation announced on 16 September 2010 which is expected to complete on or around 21 December 2010.

It remains the Directors' intention that the 15% average discount threshold and the maximum repurchase price of up to 95% of prevailing Net Asset Value per share will continue to apply to any possible future share repurchases for cancellation which result from the Company's stated discount control provision.

The Company was originally listed on the SIX Swiss Exchange in January 1997 and additionally listed on the London Stock Exchange on 5 June 2009. In US Dollar terms, CAI’s net asset value has achieved a net annualized return of 6.86%* since inception, compared to an annualized return of 2.69% for the MSCI World Index, with correlation to the index of 0.48*. Thomas Weber, partner and head of hedge fund investment management at LGT Capital Partners, has been lead portfolio manager since inception.

Mark White, General Manager of Castle Alternative Invest AG, said:

“Since the intention to list CAI in London and implement a discount control policy was announced, the discount at which the Company’s shares trade has narrowed from more than 25% to around 15% and the shares are now trading in-line with the listed fund of hedge fund sector as a whole. CAI has a longstanding track record of delivering consistent returns with low correlation to traditional asset classes and we believe it is an attractive vehicle for investors seeking diversified exposure to hedge funds.”

CAI seeks to achieve long term capital growth through investment in a well diversified and actively managed portfolio of hedge funds, managed accounts and other investment vehicles. Corporate website: www.castleai.com

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its